Jon Mcclelland Lockard

Array ( [id] => 13750801 [patent_doc_number] => 10168338 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-01 [patent_title] => Methods of identifying modulators of sestrin-gator-2 interaction for modulating mTORC1 activity [patent_app_type] => utility [patent_app_number] => 15/511007 [patent_app_country] => US [patent_app_date] => 2015-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 36 [patent_no_of_words] => 19963 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 188 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15511007 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15338895 [patent_doc_number] => 10525104 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Predictive and prognostic biomarkers related to anti-angiogenic therapy of metastatic colorectal cancer [patent_app_type] => utility [patent_app_number] => 15/509461 [patent_app_country] => US [patent_app_date] => 2015-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 5686 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 92 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15509461 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12015819 [patent_doc_number] => 09808506 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-07 [patent_title] => 'Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof' [patent_app_type] => utility [patent_app_number] => 14/847025 [patent_app_country] => US [patent_app_date] => 2015-09-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 43 [patent_no_of_words] => 20508 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14847025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13714371 [patent_doc_number] => 20170368140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-28 [patent_title] => USES OF NEUREGULIN IN PREVENTING, TREATING OR DELAYING VENTRICULAR ARRHYTHMIA, AND COMPOSITION THEREOF [patent_app_type] => utility [patent_app_number] => 15/513939 [patent_app_country] => US [patent_app_date] => 2015-09-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5584 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15513939 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10554822 [patent_doc_number] => 09279018 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841479 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39085 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841479 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10476153 [patent_doc_number] => 20150361171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-12-17 [patent_title] => 'ANTAGONIST ANTIBODIES DIRECTED AGAINST CALCITONIN GENE-RELATED PEPTIDE AND METHODS USING SAME' [patent_app_type] => utility [patent_app_number] => 14/841396 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39094 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10628737 [patent_doc_number] => 09346881 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-24 [patent_title] => 'Antagonist antibodies directed against calcitonin gene-related peptide and methods using same' [patent_app_type] => utility [patent_app_number] => 14/841440 [patent_app_country] => US [patent_app_date] => 2015-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 39107 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14841440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10806556 [patent_doc_number] => 20160152714 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-06-02 [patent_title] => 'SUBTYPES OF HUMANIZED ANTIBODY AGAINST INTERLEUKIN-6 RECEPTOR' [patent_app_type] => utility [patent_app_number] => 14/836813 [patent_app_country] => US [patent_app_date] => 2015-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 9036 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14836813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10687333 [patent_doc_number] => 20160033478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'HEMOKININ-1 RECEPTOR AND HEMOKININ-1-DERIVED PEPTIDE' [patent_app_type] => utility [patent_app_number] => 14/823378 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 11313 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14823378 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10784164 [patent_doc_number] => 20160130320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-05-12 [patent_title] => 'MODIFIED CHIMERIC POLYPEPTIDES WITH IMPROVED PHARMACOKINETIC PROPERTIES' [patent_app_type] => utility [patent_app_number] => 14/822929 [patent_app_country] => US [patent_app_date] => 2015-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 55 [patent_figures_cnt] => 55 [patent_no_of_words] => 19857 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14822929 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10684380 [patent_doc_number] => 20160030521 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-02-04 [patent_title] => 'THERAPEUTIC AGENTS COMPRISING ELASTIN-LIKE PEPTIDES' [patent_app_type] => utility [patent_app_number] => 14/822512 [patent_app_country] => US [patent_app_date] => 2015-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 69097 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14822512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10438537 [patent_doc_number] => 20150323549 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-12 [patent_title] => 'Methods for Identifying Compounds That Modulate Ion Channel Activity of a Kir Channel' [patent_app_type] => utility [patent_app_number] => 14/813396 [patent_app_country] => US [patent_app_date] => 2015-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23138 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14813396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10174858 [patent_doc_number] => 09205045 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-12-08 [patent_title] => 'Compositions comprising RANK/RANKL antagonists and related compounds for treating pain' [patent_app_type] => utility [patent_app_number] => 14/812989 [patent_app_country] => US [patent_app_date] => 2015-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 17743 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14812989 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10443320 [patent_doc_number] => 20150328332 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-11-19 [patent_title] => 'ANTI-DLL3 ANTIBODY DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 14/807789 [patent_app_country] => US [patent_app_date] => 2015-07-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 54 [patent_no_of_words] => 72465 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14807789 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10662285 [patent_doc_number] => 20160008430 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-14 [patent_title] => 'Method to Increase Bioavailability of the Delta-Opioid Receptor for Management of Pain and Neuropsychiatric Disorders' [patent_app_type] => utility [patent_app_number] => 14/799276 [patent_app_country] => US [patent_app_date] => 2015-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 9730 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14799276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10656200 [patent_doc_number] => 20160002344 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2016-01-07 [patent_title] => 'RSPO BINDING AGENTS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/795811 [patent_app_country] => US [patent_app_date] => 2015-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 53418 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14795811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10422599 [patent_doc_number] => 20150307610 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-10-29 [patent_title] => 'ANTIBODIES TO RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS (RAGE) AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 14/755301 [patent_app_country] => US [patent_app_date] => 2015-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 46829 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14755301 [rel_patent_id] =>[rel_patent_doc_number] =>)